Hepto is currently working with JigJiga University Hospital in JigJiga, the Eastern region in Ethiopia. This 342-bed teaching medical facility serves an estimated population of ten to twelve million in all east of Ethiopia and neighboring country of Somalia. Jigjiga university Hospital functions beyond its capacity. 3 Operation Theaters, Post-anesthesia care unit (PACU), Labor and delivery, male ward, female ward, pediatric ward, Intensive care unit (ICU), cesarian suction room, neonatal Intensive-care unit (NICU), Pharmacy and Emergency Room (ER) with one Ambulance, dialysis unit and outpatient clinics are struggling to cover the health needs of 10 to 12 millions in this region. There is 972 staff, including all departments and specialties.
Labor and Delivery; 88
pharmacy staff; 29
Medical Lab. 30
supporting staff; 447
Anesthesiologist; 1 (contractor)
Anesthesia Nurse; 8
Sterile processing Tech. 9
This facility is struggling to provided services to a large population, and they desperately need equipment, training, counseling, and support in every aspect of healthcare. This is the most recent annual data about this facility.
1. Total Patient served is 17,798.t
2. Outpatient service for 9,826 Patients.
3. Inpatient service for 2,153 Patients.
4. Emergency service for 3,285 Patients.
5. Delivery service for 1,060 mothers.
6. Family planning service for 108 women and Antenatal care service for 1,142 pregnant mothers.
7. Performed 165 major surgeries and 59 minor surgeries.
8. Triage, Liaison, and social service.
This only teaching and service hospital is below the standard of modern medical care in every aspect of patient care. This facility needs help and support in areas of management, infection control, proper hand hygiene, adhering aseptic techniques, triage, instrument and equipment use, and handling, environmental care, and medical record keeping. This facility needs remodeling and department re-arrangement to function smoothly.
HEPTO seeks to help this facility, affiliated university, clinics in rural areas, to the universal standard of healthcare to serve communities who dreadfully need help. First, Hepto needs a donation of medical equipment; then we train JigJiga hospital staff for new equipment which will make a significant improvement in the lives of millions. Variety of extensive training will follow until target goals reached.
Ethiopia has one of the world’s highest rates of maternal deaths and disabilities in the world. Women have a one-in-52 chance of dying from childbirth-related causes each year. Every year, more than 257,000 children under the age of five die and 120,000 die in the neonatal period. More than 60 percent of infant and 40 percent of under-five deaths in Ethiopia are neonatal deaths. We work with the Ethiopian government to reduce maternal, neonatal, and child mortality rates. We support integrated packages of evidence-based interventions delivered across a continuum of care at family, community and facility levels by increasing availability of services like skilled birth attendance and essential newborn care/treatment—especially to underserved populations.
Our achievements to benefit Ethiopian women and children include the expansion of proven interventions such as a comprehensive maternal health package through the health extension program; roll-out of basic obstetric and newborn care, essential newborn care, integrated management of neonatal and childhood illnesses, and integrated community case management of childhood illnesses including treatment of neonatal sepsis; and increased coverage of skilled birth attendance, immunizations, early identification, and care and treatment of sick children.
With malaria deaths rebounding worldwide, a pilot program testing a new and fiercely debated malaria vaccine began on Tuesday in Malawi.
Dr. Katherine O’Brien, the World Health Organization’s director of immunization, called the rollout “a historic moment in the fight against malaria,” and said the testing will soon expand to malarious regions of Ghana and Kenya.
But the vaccine, known as RTS,S, or Mosquirix, has been in development by GSK, the former GlaxoSmithKline, for more than 30 years, and it has serious drawbacks that have led some experts to argue that it does not work well enough to spend millions of dollars pursuing.
Malaria kills about 450,000 people a year, most of them young African children. Over the last 15 years, the death rate has been reduced by more than half through extensive, donor-funded efforts to hand out free mosquito nets, spray homes with insecticide and treat people with a new generation of medicines.